Core Viewpoint - Jingtai Holdings (02228) has seen a stock price increase of over 6%, currently trading at HKD 9.18 with a transaction volume of HKD 1.782 billion, following the announcement of a collaboration with South Korea's Dong-A ST to develop innovative therapies for immune and inflammatory diseases using AI and robotics [1][1][1] Group 1: Collaboration and Development - Jingtai Technology has signed a Memorandum of Understanding (MOU) with Dong-A ST to leverage its AI+ robotics research platform for drug development [1][1] - The collaboration aims to identify targets and design first-in-class or best-in-class drug candidates for immune and inflammatory diseases [1][1] Group 2: Financial Performance - Jingtai Technology has issued a profit warning, expecting a revenue of no less than RMB 500 million for the first half of the year, representing an annual increase of at least 387% [1][1] - The company anticipates turning a loss into a profit, with a net profit of no less than RMB 50 million, marking its first half-year profitability [1][1] - The financial improvement is primarily attributed to the partnership with DoveTree, which has significantly boosted revenue through AI-driven drug discovery solutions [1][1]
港股异动 | 晶泰控股(02228)涨超6% 与韩国东亚公司签署合作 公司首次实现半年盈利